Intangible Assets, Net (Genpharm , SVC Pharma , MDRNA, Teva Pharma, Cyclobenzaprine, Fentanyl, Modafinil ) (Narrative2) (Details) (USD $) In Thousands, except Share data, unless otherwise specified	0 Months Ended					3 Months Ended	12 Months Ended				1 Months Ended	12 Months Ended
	Aug. 24, 2011	Mar. 25, 2011	Jan. 05, 2011	Dec. 17, 2010	Aug. 25, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2011 Genpharm, Inc. Distribution Agreement [Member]	Jun. 30, 2008 SVC Pharma LP License And Distribution Agreement [Member] years	Dec. 31, 2011 MDRNA, Inc. Asset Purchase Agreement [Member] years	Dec. 31, 2011 Fentanyl Citrate Lozenges And Modafinil Tablets [Member]	Dec. 31, 2011 Teva Pharmaceuticals, Inc. Asset Purchase Agreement [Member]	Dec. 31, 2011 Cyclobenzaprine ER Capsules [Member]	Dec. 31, 2011 Fentanyl Citrate Lozenges [Member]	Dec. 31, 2011 Modafinil Tablets [Member]
Intangible Assets [Line Items]
Fair value of common stock sold										$ 27,300
Proceeds from issuance of common stock							333	354	238	20,800
Cash consideration received in excess of fair value over the carrying value of common stock sold										6,500
Deferred tax liability							48,814	12,703		4,300
Aggregate amount of intangible assets agreement										10,800
Fair value of net tangible and intangible assets												1,400
Estimated useful life of net tangible and intangible assets												2
Percent of interest in SVC											100.00%
Term period in year for agreement											10
Common stock shares issued							39,677,291	38,872,663		10,400,000
Cash paid to acquire rights							34,450	42,200	1,000					24,000
Payments for additional milestone launch															500
Payments allocation based on expected future cash flow													24,000			18,000	6,000
Remaining net book value of the intangible asset																16,745
Amortization period							2			15				5
Intangible asset impairment charges							27,660
Litigation settlement paid	154,000	1,700	2,500	500	2,250				3,500
Paid to acquire the intellectual property						500
Amortization expense related to intangible assets							$ 14,822	$ 16,005	$ 23,057